Detailed information for compound 220900

Basic information

Technical information
  • TDR Targets ID: 220900
  • Name: 6-[(Z)-1-(2,5-difluorophenyl)but-1-en-3-ynyl] -1-propan-2-ylsulfonylbenzimidazol-2-amine
  • MW: 401.43 | Formula: C20H17F2N3O2S
  • H donors: 1 H acceptors: 3 LogP: 5.09 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: C#C/C=C(\c1cc(F)ccc1F)/c1ccc2c(c1)n(c(n2)N)S(=O)(=O)C(C)C
  • InChi: 1S/C20H17F2N3O2S/c1-4-5-15(16-11-14(21)7-8-17(16)22)13-6-9-18-19(10-13)25(20(23)24-18)28(26,27)12(2)3/h1,5-12H,2-3H3,(H2,23,24)/b15-5-
  • InChiKey: PXLPGAWAWWMGDL-WCSRMQSCSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 6-[(Z)-1-(2,5-difluorophenyl)but-1-en-3-ynyl]-1-isopropylsulfonyl-benzimidazol-2-amine
  • 6-[(Z)-1-(2,5-difluorophenyl)but-1-en-3-ynyl]-1-isopropylsulfonyl-2-benzimidazolamine
  • 6-[(Z)-1-(2,5-difluorophenyl)but-1-en-3-ynyl]-1-propan-2-ylsulfonyl-benzimidazol-2-amine
  • [6-[(Z)-1-(2,5-difluorophenyl)but-1-en-3-ynyl]-1-isopropylsulfonyl-benzimidazol-2-yl]amine
  • AIDS-191658
  • AIDS191658
  • 1H-Benzimidazol-2-amine, 6-[(1Z)-1-(2,5-difluorophenyl)-1-buten-3-ynyl]-1-[(1-methylethyl)sulfonyl]-

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis Basic leucine zipper (bZIP) transcription 0.0038 1 1
Mycobacterium tuberculosis Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) 0.002 0.3224 0.5
Schistosoma mansoni insulysin unit 3 (M16 family) 0.0025 0.5256 0.4695
Schistosoma mansoni nardilysin (M16 family) 0.0025 0.5256 0.4695
Wolbachia endosymbiont of Brugia malayi exonuclease III 0.002 0.3224 0.5
Chlamydia trachomatis insulinase family protease III 0.0025 0.5256 0.5
Loa Loa (eye worm) insulin-degrading enzyme 0.0025 0.5256 1
Entamoeba histolytica hypothetical protein 0.0038 1 1
Echinococcus multilocularis insulin degrading enzyme 0.0025 0.5256 0.4404
Echinococcus granulosus nardilysin 0.0025 0.5256 0.5256
Trypanosoma cruzi peptidase, putative 0.0025 0.5256 1
Toxoplasma gondii insulysin, putative 0.0024 0.4792 0.9116
Toxoplasma gondii peptidase M16 inactive domain-containing protein 0.0015 0.1523 0.2898
Echinococcus granulosus Basic leucine zipper bZIP transcription 0.0038 1 1
Leishmania major phosphoglycan beta 1,3 galactosyltransferase 5 0.0025 0.5256 1
Entamoeba histolytica hypothetical protein 0.0038 1 1
Schistosoma mansoni transcription factor LCR-F1 0.0038 1 1
Echinococcus granulosus 3'partial|nardilysin 0.0025 0.5256 0.5256
Plasmodium falciparum AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative 0.002 0.3224 0.5
Echinococcus granulosus DNA apurinic or apyrimidinic site lyase 0.002 0.3224 0.3224
Brugia malayi insulin-degrading enzyme 0.0025 0.5256 0.2999
Schistosoma mansoni ap endonuclease 0.002 0.3224 0.2422
Trypanosoma brucei peptidase, putative 0.0025 0.5256 1
Toxoplasma gondii exonuclease III APE 0.002 0.3224 0.6133
Trypanosoma cruzi peptidase, putative 0.0025 0.5256 1
Entamoeba histolytica hypothetical protein 0.0038 1 1
Plasmodium vivax AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative 0.002 0.3224 0.5
Schistosoma mansoni insulysin unit 3 (M16 family) 0.0025 0.5256 0.4695
Entamoeba histolytica hypothetical protein 0.0038 1 1
Echinococcus multilocularis nardilysin 0.0025 0.5256 0.4404
Trichomonas vaginalis ap endonuclease, putative 0.002 0.3224 0.5
Mycobacterium ulcerans exodeoxyribonuclease III protein XthA 0.002 0.3224 0.5
Giardia lamblia Endonuclease/Exonuclease/phosphatase 0.002 0.3224 0.5
Echinococcus multilocularis nardilysin 0.0025 0.5256 0.4404
Trichomonas vaginalis ap endonuclease, putative 0.002 0.3224 0.5
Schistosoma mansoni hypothetical protein 0.0038 1 1
Echinococcus granulosus insulin degrading enzyme 0.0025 0.5256 0.5256
Schistosoma mansoni ap endonuclease 0.002 0.3224 0.2422
Echinococcus multilocularis DNA (apurinic or apyrimidinic site) lyase 0.002 0.3224 0.2006
Toxoplasma gondii rhoptry metalloprotease toxolysin TLN1 0.0025 0.5256 1
Schistosoma mansoni nardilysin (M16 family) 0.0025 0.5256 0.4695
Toxoplasma gondii sporozoite developmental protein 0.0025 0.5256 1
Treponema pallidum exodeoxyribonuclease (exoA) 0.002 0.3224 0.5

Activities

Activity type Activity value Assay description Source Reference
Cmax (ADMET) = 9.3 ug ml-1 Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame. ChEMBL. 9397174
Cmax (ADMET) = 9.300000000000004 ug ml-1 Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame. ChEMBL. 9397174
IC50 (functional) = 0.032 ug ml-1 Antiviral activity of the compound against poliovirus 1 ChEMBL. 9397174
IC50 (functional) = 0.069 ug ml-1 Antiviral activity of the compound against coxsackie virus A21 ChEMBL. 9397174
IC50 (functional) = 0.079 ug ml-1 Antiviral activity of the compound against human rhinovirus 2 ChEMBL. 9397174
IC50 (functional) = 0.096 ug ml-1 Antiviral activity of the compound against human rhinovirus 1A ChEMBL. 9397174
IC50 (functional) = 0.099 ug ml-1 Antiviral activity of the compound against human rhinovirus 16 ChEMBL. 9397174
IC50 (functional) = 0.1 ug ml-1 Antiviral activity of the compound against coxsackie virus A21M ChEMBL. 9397174
IC50 (functional) = 0.1 ug ml-1 Antiviral activity of the compound against coxsackie virus B3 ChEMBL. 9397174
IC50 (functional) = 0.11 ug ml-1 Antiviral activity of the compound against human rhinovirus 14 using plaque reduction assay in HeLa cell lines ChEMBL. 9397174
TC50 (ADMET) = 63 ug ml-1 Antiviral activity against human rhinovirus 14 (HRV-14) using CPE/XTT assay in human tumor cell lines. ChEMBL. 9397174

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.